440 related articles for article (PubMed ID: 15956649)
21. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Brown PD; Krishnan S; Sarkaria JN; Wu W; Jaeckle KA; Uhm JH; Geoffroy FJ; Arusell R; Kitange G; Jenkins RB; Kugler JW; Morton RF; Rowland KM; Mischel P; Yong WH; Scheithauer BW; Schiff D; Giannini C; Buckner JC;
J Clin Oncol; 2008 Dec; 26(34):5603-9. PubMed ID: 18955445
[TBL] [Abstract][Full Text] [Related]
23. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; Namgyal C; Kawasaki T; Kinsella K; Michelini AL; Enzinger PC; Kulke MH; Ryan DP; Loda M; Fuchs CS
Clin Cancer Res; 2005 Sep; 11(18):6650-6. PubMed ID: 16166444
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
van den Bent MJ; Brandes AA; Rampling R; Kouwenhoven MC; Kros JM; Carpentier AF; Clement PM; Frenay M; Campone M; Baurain JF; Armand JP; Taphoorn MJ; Tosoni A; Kletzl H; Klughammer B; Lacombe D; Gorlia T
J Clin Oncol; 2009 Mar; 27(8):1268-74. PubMed ID: 19204207
[TBL] [Abstract][Full Text] [Related]
25. PAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation.
Fiano V; Ghimenti C; Imarisio S; Silengo L; Schiffer D
Anticancer Res; 2004; 24(5A):2643-7. PubMed ID: 15517868
[TBL] [Abstract][Full Text] [Related]
26. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
28. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
[TBL] [Abstract][Full Text] [Related]
29. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Zhao Q; Kretschmer N; Bauer R; Efferth T
Int J Cancer; 2015 Sep; 137(6):1446-56. PubMed ID: 25688715
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
[TBL] [Abstract][Full Text] [Related]
31. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Endoh H; Yatabe Y; Kosaka T; Kuwano H; Mitsudomi T
J Thorac Oncol; 2006 Sep; 1(7):629-34. PubMed ID: 17409929
[TBL] [Abstract][Full Text] [Related]
32. Dysregulated PTEN-PKB and negative receptor status in human breast cancer.
Shi W; Zhang X; Pintilie M; Ma N; Miller N; Banerjee D; Tsao MS; Mak T; Fyles A; Liu FF
Int J Cancer; 2003 Mar; 104(2):195-203. PubMed ID: 12569575
[TBL] [Abstract][Full Text] [Related]
33. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Momota H; Nerio E; Holland EC
Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
[TBL] [Abstract][Full Text] [Related]
34. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
[TBL] [Abstract][Full Text] [Related]
35. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
Halatsch ME; Gehrke EE; Vougioukas VI; Bötefür IC; A-Borhani F; Efferth T; Gebhart E; Domhof S; Schmidt U; Buchfelder M
J Neurosurg; 2004 Mar; 100(3):523-33. PubMed ID: 15035290
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
37. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
38. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
39. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
[TBL] [Abstract][Full Text] [Related]
40. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Lassman AB; Rossi MR; Raizer JJ; Abrey LE; Lieberman FS; Grefe CN; Lamborn K; Pao W; Shih AH; Kuhn JG; Wilson R; Nowak NJ; Cowell JK; DeAngelis LM; Wen P; Gilbert MR; Chang S; Yung WA; Prados M; Holland EC
Clin Cancer Res; 2005 Nov; 11(21):7841-50. PubMed ID: 16278407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
